Friday 16 October 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.99
0.00
0.00%
Follow LRMR
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 34.68 | 38.16 | 55.20 | 7.44 | 7.43 | 7.00 | 1.53 | 2.18 | 3.01 | 1.61 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 146.16 | 65.52 | 148.26 | 65.40 | 25.87 | 23.95 | 11.05 | 6.85 | 13.68 | 5.37 | |||||
| People | |||||||||||||||
| People | Employees | 32 | 35 | 38 | 7 | 28 | 31 | 26 | 42 | 65 | 71 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (58) | (52) | (61) | (23) | (42) | (51) | (35) | (37) | (81) | (166) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (58) | (52) | (61) | (23) | (42) | (51) | (35) | (37) | (81) | (166) | |||||
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | (2) | (5) | (1) | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (25.45) | (22.81) | (22.81) | (3.80) | (3.57) | (2.95) | (1.37) | (0.84) | (1.32) | (2.27) | |||||
| Cash flow | (22.86) | (19.16) | (19.18) | (3.73) | (3.55) | (2.45) | (1.07) | (0.76) | (1.16) | (1.55) | |||||
| Capex | (0.29) | (0.02) | (0.04) | (0.01) | (0.01) | (0.02) | 0.00 | 0.00 | (0.01) | 0.00 | |||||
| Free cash flow | (23.15) | (19.18) | (19.22) | (3.74) | (3.56) | (2.47) | (1.07) | (0.77) | (1.16) | (1.55) | |||||
| Book value | 53.53 | 34.23 | 34.74 | (0.11) | 7.55 | 3.75 | 4.31 | 1.86 | 2.80 | 1.07 | |||||
| Shares, m | 2 | 2 | 3 | 6 | 12 | 17 | 26 | 44 | 61 | 73 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (52) | (44) | (51) | (23) | (42) | (42) | (28) | (33) | (71) | (113) | ||||
| Capex | (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | |||||
| Free cash flow | (53) | (44) | (52) | (23) | (42) | (42) | (28) | (34) | (71) | (113) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 121 | 98 | 108 | (1) | 89 | 63 | 110 | 81 | 171 | 77 | ||||
| Total debt | 4 | 20 | 15 | 8 | 6 | 5 | 5 | — | — | — | |||||
| Net debt | (129) | (82) | (103) | (1) | (93) | (70) | (118) | (87) | (183) | (137) | |||||
| Shareholders’ equity | 122 | 78 | 93 | (1) | 90 | 64 | 111 | 82 | 172 | 78 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (36.09) | (43.88) | (54.00) | (36.44) | (77.32) | (55.23) | (34.48) | (33.24) | (54.43) | (95.75) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | (39.80) | (52.04) | (71.57) | (49.97) | (95.47) | (65.72) | (40.33) | (38.36) | (63.58) | (132.59) | |||||
Negative figures in brackets.
Charts ten years each
Larimar Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics, Inc. | $226.6M | — (loss-making) | — (loss-making) | — | n/m | +35.58% (above 0%: growing) | 0.00% | 0.00% | Compare |
| KROS Keros Therapeutics, Inc. | $220.1M | — (loss-making) | — (loss-making) | −99.83% (below 0%: shrinking) | n/m | +32.19% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CAMP CAMP4 Therapeutics Corporation | $216.5M | — (loss-making) | — (loss-making) | +18.84% (above 0%: growing) | n/m | −23.90% (below 0%: shrinking) | 100.00% | (752.11%) | Compare |
| PYXS Pyxis Oncology, Inc. | $215.3M | — (loss-making) | — (loss-making) | — | n/m | −5.46% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EVMN Evommune Inc. | $215.2M | — (loss-making) | — (loss-making) | — | n/m | +21.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $214.7M | — (loss-making) | — (loss-making) | +377.97% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| ZNTL Zentalis Pharmaceuticals, Inc. | $212.1M | — (loss-making) | — (loss-making) | — | n/m | −9.06% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LRMR Larimar Therapeutics, Inc. | $206.7M | — (loss-making) | — | — | n/m | −127.63% (below 0%: shrinking) | 0.00% | 0.00% | |
| ADCT ADC Therapeutics SA | $190.2M | — (loss-making) | — (loss-making) | +2.17% (above 0%: growing) | n/m | +50.98% (above 0%: growing) | 87.80% | (132.03%) | Compare |
| Median of peers | $215.2M | — | — | +10.51% | — | +17.33% | 100.00% | 0.00% |
Larimar Therapeutics, Inc. (LRMR) key facts
- Larimar Therapeutics, Inc. (LRMR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, LRMR traded at $1.99, a market capitalization of $206.7 million.
- Return on equity was −132.6% and debt-to-equity 0.00.